Printer Friendly

Aastrom Biosciences initiates new product program for treatment of bone related diseases.

Aastrom Biosciences, Inc., Ann Arbor, MI, announced it has initiated a program to develop its cell production technology and AastromReplicell System in the treatment of bone related diseases. The company says the program is intended to result in a new therapy kit for use with the AastromReplicell System, which will be designed to produce therapeutic quantities of bone-forming cells in the treatment of bone degenerative diseases such as Osteoporosis.

Using the system, the production of bone-forming cells will begin with a small sample of cells, taken from a patient or donor. The product, designated the OC-I Therapy Kit, will be used to expand the small sample into a large quantity of the therapeutic bone-forming cells, Aastrom says. The new cells will then be infused into the patient, where they are to migrate to the bone areas, with the targeted result being the formation of new bone.

Contact: Todd Simpson - (734) 930-5777
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Aastrom Biosciences initiates new product program for treatment of bone related diseases.
Publication:Transplant News
Geographic Code:1USA
Date:Apr 28, 2000
Words:151
Previous Article:Eon Labs, Mylan Pharmaceuticals enter agreement to co-promote generic cyclosporine softgel capsules to hospitals.
Next Article:ASTS creating National Registry of all living donor liver transplant procedures to help assess risk.
Topics:


Related Articles
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom enters distribution agreements with Gambro and Micromin to distribute AastromReplicell System.
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Amarillo Biosciences announces agreement regarding interferon gamma with Molecular Medicine.
Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.
Aastrom receives patent expanding coverage for its single-pass perfusion technology.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |